Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Common Equity: 2016-2025

Historic Common Equity for Rhythm Pharmaceuticals (RYTM) over the last 8 years, with Sep 2025 value amounting to $148.8 million.

  • Rhythm Pharmaceuticals' Common Equity rose 1226.95% to $148.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $148.8 million, marking a year-over-year increase of 1226.95%. This contributed to the annual value of $21.7 million for FY2024, which is 87.20% down from last year.
  • Latest data reveals that Rhythm Pharmaceuticals reported Common Equity of $148.8 million as of Q3 2025, which was up 1,349.72% from -$11.9 million recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Common Equity peaked at $380.9 million during Q1 2021, and registered a low of -$11.9 million during Q2 2025.
  • Moreover, its 3-year median value for Common Equity was $61.6 million (2024), whereas its average is $96.3 million.
  • Examining YoY changes over the last 5 years, Rhythm Pharmaceuticals' Common Equity showed a top increase of 1,226.95% in 2025 and a maximum decrease of 130.27% in 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Common Equity (Quarterly) stood at $284.2 million in 2021, then declined by 7.00% to $264.3 million in 2022, then crashed by 35.76% to $169.8 million in 2023, then plummeted by 87.20% to $21.7 million in 2024, then skyrocketed by 1,226.95% to $148.8 million in 2025.
  • Its Common Equity was $148.8 million in Q3 2025, compared to -$11.9 million in Q2 2025 and $18.9 million in Q1 2025.